Skip to main content
SpringerLink
Log in

Topical Mesalamine

  • Chapter
  • First Online:
Medical Therapy of Ulcerative Colitis

  • 1286 Accesses

Abstract

Proctitis and left-sided colitis represent the majority of newly diagnosed ulcerative colitis cases. Affected patients, with inflammation limited to the distal 60 cm of the colon, can be effectively treated with both oral and topical mesalamine formulations. The current 2010 American College of Gastroenterology guidelines state that for mild to moderate distal ulcerative colitis, topical mesalamine is superior to oral mesalamine or topical steroids. Furthermore, the combination of oral and topical mesalamine is more effective than either agent alone.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 199.00
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Ekbom A, Helmick C, Zack M, Adami HO. Ulcerative proctitis in central Sweden 1965-1983. A population-based epidemiological study. Dig Dis Sci. 1991;36(1):97–102.

    Article  CAS  PubMed  Google Scholar 

  2. Jess T, Riis L, Vind I, et al. Changes in clinical characteristics, course, and prognosis of inflammatory bowel disease during the last 5 decades: a population-based study from Copenhagen, Denmark. Inflamm Bowel Dis. 2007;13(4):481–9.

    Article  PubMed  Google Scholar 

  3. Langholz E. Ulcerative colitis. An epidemiological study based on a regional inception cohort, with special reference to disease course and prognosis. Dan Med Bull. 1999;46(5):400–15.

    CAS  PubMed  Google Scholar 

  4. Kornbluth A, Sachar DB, Practice Parameters Committee of the American College of Gastroenterology. Ulcerative colitis practice guidelines in adults: American College of Gastroenterology, Practice Parameters Committee. Am J Gastroenterol. 2010;105(3):501–23.

    Article  PubMed  Google Scholar 

  5. Baron JH, Connell AM, Lennard-Jones JE, Jones FA. Sulphasalazine and salicylazosulphadimidine in ulcerative colitis. Lancet. 1962;1(7239):1094–6.

    Article  CAS  PubMed  Google Scholar 

  6. Svartz N. Salazopyrin, a new sulfanilamide preparation. Acta Medica Scand. 1942;110:577.

    Article  Google Scholar 

  7. Svartz N. Behandlund der ulzerosen kolitis mit salazopyrin. Gastroenterologia. 1941/1942;66:312.

    Google Scholar 

  8. Azad Khan AK, Piris J, Truelove SC. An experiment to determine the active therapeutic moiety of sulphasalazine. Lancet. 1977;2(8044):892–5.

    Article  CAS  PubMed  Google Scholar 

  9. Peppercorn MA. Sulfasalazine. Pharmacology, clinical use, toxicity, and related new drug development. Ann Intern Med. 1984;101(3):377–86.

    Article  CAS  PubMed  Google Scholar 

  10. Peppercorn MA, Goldman P. The role of intestinal bacteria in the metabolism of salicylazosulfapyridine. J Pharmacol Exp Ther. 1972;181(3):555–62.

    CAS  PubMed  Google Scholar 

  11. Campieri M, Lanfranchi GA, Bazzocchi G, et al. Treatment of ulcerative colitis with high-dose 5-aminosalicylic acid enemas. Lancet. 1981;2(8241):270–1.

    Article  CAS  PubMed  Google Scholar 

  12. Palmer KR, Goepel JR, Holdsworth CD. Sulphasalazine retention enemas in ulcerative colitis: a double-blind trial. Br Med J (Clin Res Ed). 1981;282(6276):1571–3.

    Article  CAS  Google Scholar 

  13. Frimberger E, Fruhmorgen P, Kuhner W, Ottenjann R. Sulfasalazine enema in acute left-sided ulcerative colitis (author's transl). MMW Munch Med Wochenschr. 1980;122(36):1233–5.

    CAS  PubMed  Google Scholar 

  14. De Vos M, Verdievel H, Schoonjans R, Praet M, Bogaert M, Barbier F. Concentrations of 5-ASA and ac-5-ASA in human ileocolonic biopsy homogenates after oral 5-ASA preparations. Gut. 1992;33(10):1338–42.

    Article  PubMed Central  PubMed  Google Scholar 

  15. Nugent SG, Kumar D, Rampton DS, Evans DF. Intestinal luminal pH in inflammatory bowel disease: possible determinants and implications for therapy with aminosalicylates and other drugs. Gut. 2001;48(4):571–7.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  16. Haddish-Berhane N, Farhadi A, Nyquist C, Haghighi K, Keshavarzian A. Biological variability and targeted delivery of therapeutics for inflammatory bowel diseases: an in silico approach. Inflamm Allergy Drug Targets. 2007;6(1):47–55.

    Article  CAS  PubMed  Google Scholar 

  17. Frieri G, Pimpo MT, Palumbo GC, et al. Rectal and colonic mesalazine concentration in ulcerative colitis: oral vs. oral plus topical treatment. Aliment Pharmacol Ther. 1999;13(11):1413–7.

    Article  CAS  PubMed  Google Scholar 

  18. Frieri G, Giacomelli R, Pimpo M, et al. Mucosal 5-aminosalicylic acid concentration inversely correlates with severity of colonic inflammation in patients with ulcerative colitis. Gut. 2000;47(3):410–4.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  19. Williams CN, Haber G, Aquino JA. Double-blind, placebo-controlled evaluation of 5-ASA suppositories in active distal proctitis and measurement of extent of spread using 99mTc-labeled 5-ASA suppositories. Dig Dis Sci. 1987;32(12 Suppl):71S–5.

    Article  CAS  PubMed  Google Scholar 

  20. Andus T, Kocjan A, Muser M, et al. Clinical trial: A novel high-dose 1 g mesalamine suppository (Salofalk) once daily is as efficacious as a 500-mg suppository thrice daily in active ulcerative proctitis. Inflamm Bowel Dis. 2010;16(11):1947–56.

    Article  PubMed  Google Scholar 

  21. Pokrotnieks J, Marlicz K, Paradowski L, Margus B, Zaborowski P, Greinwald R. Efficacy and tolerability of mesalazine foam enema (Salofalk foam) for distal ulcerative colitis: a double-blind, randomized, placebo-controlled study. Aliment Pharmacol Ther. 2000;14(9):1191–8.

    Article  CAS  PubMed  Google Scholar 

  22. Campieri M, Corbelli C, Gionchetti P, et al. Spread and distribution of 5-ASA colonic foam and 5-ASA enema in patients with ulcerative colitis. Dig Dis Sci. 1992;37(12):1890–7.

    Article  CAS  PubMed  Google Scholar 

  23. Eliakim R, Tulassay Z, Kupcinskas L. Clinical trial: randomized-controlled clinical study comparing the efficacy and safety of a low-volume vs. a high-volume mesalazine foam in active distal ulcerative colitis. Aliment Pharmacol Ther. 2007;26(9):1237–49.

    Article  CAS  PubMed  Google Scholar 

  24. Gionchetti P, Venturi A, Rizzello F, et al. Retrograde colonic spread of a new mesalazine rectal enema in patients with distal ulcerative colitis. Aliment Pharmacol Ther. 1997;11(4):679–84.

    Article  CAS  PubMed  Google Scholar 

  25. Gionchetti P, Ardizzone S, Benvenuti ME, et al. A new mesalazine gel enema in the treatment of left-sided ulcerative colitis: a randomized controlled multicentre trial. Aliment Pharmacol Ther. 1999;13(3):381–8.

    Article  CAS  PubMed  Google Scholar 

  26. Marshall JK, Thabane M, Steinhart AH, Newman JR, Anand A, Irvine EJ. Rectal 5-aminosalicylic acid for induction of remission in ulcerative colitis. Cochrane Database Syst Rev. 2010;1, CD004115.

    PubMed  Google Scholar 

  27. Cohen RD, Woseth DM, Thisted RA, Hanauer SB. A meta-analysis and overview of the literature on treatment options for left-sided ulcerative colitis and ulcerative proctitis. Am J Gastroenterol. 2000;95(5):1263–76.

    Article  CAS  PubMed  Google Scholar 

  28. Campieri M, De Franchis R, Bianchi Porro G, Ranzi T, Brunetti G, Barbara L. Mesalazine (5-aminosalicylic acid) suppositories in the treatment of ulcerative proctitis or distal proctosigmoiditis. A randomized controlled trial. Scand J Gastroenterol. 1990;25(7):663–8.

    Article  CAS  PubMed  Google Scholar 

  29. d'Albasio G, Paoluzi P, Campieri M, et al. Maintenance treatment of ulcerative proctitis with mesalazine suppositories: a double-blind placebo-controlled trial. The Italian IBD study group. Am J Gastroenterol. 1998;93(5):799–803.

    Article  PubMed  Google Scholar 

  30. Campieri M, Gionchetti P, Belluzzi A, et al. Topical treatment with 5-aminosalicylic in distal ulcerative colitis by using a new suppository preparation. A double-blind placebo controlled trial. Int J Colorectal Dis. 1990;5(2):79–81.

    Article  CAS  PubMed  Google Scholar 

  31. Williams CN. Efficacy and tolerance of 5-aminosalicylic acid suppositories in the treatment of ulcerative proctitis: a review of two double-blind placebo controlled trials. Can J Gastroenterol. 1990;4:472.

    Google Scholar 

  32. Lee FI, Jewell DP, Mani V, et al. A randomised trial comparing mesalazine and prednisolone foam enemas in patients with acute distal ulcerative colitis. Gut. 1996;38(2):229–33.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  33. Danish 5-ASA Group. Topical 5-aminosalicylic acid versus prednisolone in ulcerative proctosigmoiditis. A randomized, double-blind multicenter trial. Dig Dis Sci. 1987;32(6):598–602.

    Article  Google Scholar 

  34. Biancone L, Gionchetti P, Blanco Gdel V, et al. Beclomethasone dipropionate versus mesalazine in distal ulcerative colitis: a multicenter, randomized, double-blind study. Dig Liver Dis. 2007;39(4):329–37.

    Article  CAS  PubMed  Google Scholar 

  35. Gionchetti P, D'Arienzo A, Rizzello F, et al. Topical treatment of distal active ulcerative colitis with beclomethasone dipropionate or mesalamine: a single-blind randomized controlled trial. J Clin Gastroenterol. 2005;39(4):291–7.

    Article  CAS  PubMed  Google Scholar 

  36. Farup PG, Hovde O, Halvorsen FA, Raknerud N, Brodin U. Mesalazine suppositories versus hydrocortisone foam in patients with distal ulcerative colitis. A comparison of the efficacy and practicality of two topical treatment regimens. Scand J Gastroenterol. 1995;30(2):164–70.

    Article  CAS  PubMed  Google Scholar 

  37. Lemann M, Galian A, Rutgeerts P, et al. Comparison of budesonide and 5-aminosalicylic acid enemas in active distal ulcerative colitis. Aliment Pharmacol Ther. 1995;9(5):557–62.

    Article  CAS  PubMed  Google Scholar 

  38. Ford AC, Khan KJ, Achkar JP, Moayyedi P. Efficacy of oral vs. topical, or combined oral and topical 5-aminosalicylates, in ulcerative colitis: systematic review and meta-analysis. Am J Gastroenterol. 2012;107(2):167–76.

    Article  CAS  PubMed  Google Scholar 

  39. Gionchetti P, Rizzello F, Venturi A, et al. Comparison of oral with rectal mesalazine in the treatment of ulcerative proctitis. Dis Colon Rectum. 1998;41(1):93–7.

    Article  CAS  PubMed  Google Scholar 

  40. Kam L, Cohen H, Dooley C, Rubin P, Orchard J. A comparison of mesalamine suspension enema and oral sulfasalazine for treatment of active distal ulcerative colitis in adults. Am J Gastroenterol. 1996;91(7):1338–42.

    CAS  PubMed  Google Scholar 

  41. Prantera C, Viscido A, Biancone L, Francavilla A, Giglio L, Campieri M. A new oral delivery system for 5-ASA: preliminary clinical findings for MMx. Inflamm Bowel Dis. 2005;11(5):421–7.

    Article  PubMed  Google Scholar 

  42. Safdi M, DeMicco M, Sninsky C, et al. A double-blind comparison of oral versus rectal mesalamine versus combination therapy in the treatment of distal ulcerative colitis. Am J Gastroenterol. 1997;92(10):1867–71.

    CAS  PubMed  Google Scholar 

  43. Marteau P, Probert CS, Lindgren S, et al. Combined oral and enema treatment with Pentasa (mesalazine) is superior to oral therapy alone in patients with extensive mild/moderate active ulcerative colitis: a randomised, double blind, placebo controlled study. Gut. 2005;54(7):960–5.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  44. Fruhmorgen P, Demling L. On the efficacy of ready-made-up commercially available salicylazosulphapyridine enemas in the treatment of proctitis, proctosigmoiditis and ulcerative colitis involving rectum, sigmoid and descending colon. Hepatogastroenterology. 1980;27(6):473–6.

    CAS  PubMed  Google Scholar 

  45. Vecchi M, Meucci G, Gionchetti P, et al. Oral versus combination mesalazine therapy in active ulcerative colitis: a double-blind, double-dummy, randomized multicentre study. Aliment Pharmacol Ther. 2001;15(2):251–6.

    Article  CAS  PubMed  Google Scholar 

  46. Marteau P, Crand J, Foucault M, Rambaud JC. Use of mesalazine slow release suppositories 1 g three times per week to maintain remission of ulcerative proctitis: a randomised double blind placebo controlled multicentre study. Gut. 1998;42(2):195–9.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  47. Hanauer S, Good LI, Goodman MW, et al. Long-term use of mesalamine (Rowasa) suppositories in remission maintenance of ulcerative proctitis. Am J Gastroenterol. 2000;95(7):1749–54.

    Article  CAS  PubMed  Google Scholar 

  48. D'Arienzo A, Panarese A, D'Armiento FP, et al. 5-aminosalicylic acid suppositories in the maintenance of remission in idiopathic proctitis or proctosigmoiditis: a double-blind placebo-controlled clinical trial. Am J Gastroenterol. 1990;85(9):1079–82.

    PubMed  Google Scholar 

  49. Biddle WL, Greenberger NJ, Swan JT, McPhee MS, Miner Jr PB. 5-aminosalicylic acid enemas: effective agent in maintaining remission in left-sided ulcerative colitis. Gastroenterology. 1988;94(4):1075–9.

    CAS  PubMed  Google Scholar 

  50. Miner P, Daly R, Nester T. The effect of varying dose intervals of mesalamine enemas for the prevention of relapse in distal ulcerative colitis. Gastroenterology. 1994;106 Suppl 2:A736.

    Google Scholar 

  51. d'Albasio G, Pacini F, Camarri E, et al. Combined therapy with 5-aminosalicylic acid tablets and enemas for maintaining remission in ulcerative colitis: a randomized double-blind study. Am J Gastroenterol. 1997;92(7):1143–7.

    PubMed  Google Scholar 

  52. Yokoyama H, Takagi S, Kuriyama S, et al. Effect of weekend 5-aminosalicylic acid (mesalazine) enema as maintenance therapy for ulcerative colitis: results from a randomized controlled study. Inflamm Bowel Dis. 2007;13(9):1115–20.

    Article  PubMed  Google Scholar 

  53. Pimpo MT, Galletti B, Palumbo G, et al. Mesalazine vanishing time from rectal mucosa following its topical administration. J Crohns Colitis. 2010;4(1):102–5.

    Article  CAS  PubMed  Google Scholar 

  54. Harris MS, Lichtenstein GR. Review article: delivery and efficacy of topical 5-aminosalicylic acid (mesalazine) therapy in the treatment of ulcerative colitis. Aliment Pharmacol Ther. 2011;33(9):996–1009.

    Article  CAS  PubMed  Google Scholar 

  55. Kane SV, Accortt NA, Magowan S, Brixner D. Predictors of persistence with 5-aminosalicylic acid therapy for ulcerative colitis. Aliment Pharmacol Ther. 2009;29(8):855–62.

    Article  CAS  PubMed  Google Scholar 

  56. D'Inca R, Bertomoro P, Mazzocco K, Vettorato MG, Rumiati R, Sturniolo GC. Risk factors for non-adherence to medication in inflammatory bowel disease patients. Aliment Pharmacol Ther. 2008;27(2):166–72.

    Article  PubMed  Google Scholar 

  57. Marshall JK, Irvine EJ. Putting rectal 5-aminosalicylic acid in its place: the role in distal ulcerative colitis. Am J Gastroenterol. 2000;95(7):1628–36.

    Article  CAS  PubMed  Google Scholar 

  58. Hanauer SB, Robinson M, Pruitt R, et al. Budesonide enema for the treatment of active, distal ulcerative colitis and proctitis: a dose-ranging study. U.S. Budesonide Enema Study Group. Gastroenterology. 1998;115(3):525–32.

    Article  CAS  PubMed  Google Scholar 

  59. Campieri M, Gionchetti P, Beluzzi A, et al. Sucralfate 5-aminosalicylic acid and placebo enemas in the treatment of ulcerative colitis. Eur J Gastroenterol Hepatol. 1991;3:41–4.

    Google Scholar 

  60. Campieri M, Gionchetti P, Belluzi A, et al. Optimum dosage of 5-aminosalicylic acid as rectal enemas in patients with active ulcerative colitis. Gut. 1991;32(8):929–31.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  61. Moller C, Kiviluoto O, Santavirta S. Local treatment of ulcerative proctitis with Salicylazosulphapyridine (Salazopyrin) enema. Clin Trials J. 1978;15(6):199–203.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medicine, Section of Gastroenterology, The University of Chicago Medical Center, Chicago, IL, USA

    Sushila Dalal M.D.

  2. Gastroenterology Division, Section of Gastroenterology, Department of Medicine, Inflammatory Bowel Disease Center, The University of Chicago Medical Center, 5841 S. Maryland Ave., MC4076, Chicago, 60637-1463, IL, USA

    Russell D. Cohen M.D.

Authors
  1. Sushila Dalal M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Russell D. Cohen M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Sushila Dalal M.D. .

Editor information

Editors and Affiliations

  1. Gastroenterology Division, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA

    Gary R. Lichtenstein

Rights and permissions

Reprints and permissions

Copyright information

© 2014 Springer Science+Business Media New York

About this chapter

Cite this chapter

Dalal, S., Cohen, R.D. (2014). Topical Mesalamine. In: Lichtenstein, G. (eds) Medical Therapy of Ulcerative Colitis. Springer, New York, NY. https://doi.org/10.1007/978-1-4939-1677-1_8

Download citation

  • DOI: https://doi.org/10.1007/978-1-4939-1677-1_8

  • Published:

  • Publisher Name: Springer, New York, NY

  • Print ISBN: 978-1-4939-1676-4

  • Online ISBN: 978-1-4939-1677-1

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation